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Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are reported to be associated with poor
prognosis, depending on their pro-tumoral roles. Current knowledge of TAMs and CAFs in the tumor microenvironment of
urothelial cancer of the bladder (UCB) is limited. Therefore,we investigated the paracrine effect inducedby TAMs andCAFs in
the tumor microenvironment of human UCB. For this, we first carried out immunohistochemical analysis for CXCL1, CD204
(TAM marker), αSMA (CAF marker), E-cadherin, and MMP2 using 155 UBC tissue samples. Next, CXCL1-overexpressing
clones of THP-1-derived TAMs and NIH3T3-derived CAFs were developed by lentiviral vector infection. The immunohisto-
chemical study showed high CXCL1 levels in UCB cells to be associated with enhanced recruitment of TAMs/CAFs, higher
metastatic potential, and poor prognosis. Three-dimensional (3D) co-culture of UCB cells and TAMs/CAFs suggested that
CXCL1 production in TAMs/CAFs play an important role in cell-to-cell adhesion and interaction among cancer cells and these
stromal cells. CXCL1-expressing TAMs/CAFs enhanced tumor growth of subcutaneous UCB tumors in nude mice when
injected together. In addition, an experiment using the orthotopic bladder cancer model revealed that CXCL1 production in
TAMs/CAFs supported tumor implantation into themurine bladder wall and UCB growthwhen injected together, whichwas
confirmed by clinical data of patients with bladder cancer. Thus, CXCL1 signaling in the tumor microenvironment is highly
responsible for repeated intravesical recurrence, disease progression, and drug resistance through enhanced invasion ability.
In conclusion, disruptingCXCL1 signaling to dysregulate this chemokine is a promising therapeutic approach for humanUCB.
Neoplasia (2016) 18, 636–646
Address all correspondence to Makito Miyake, Department of Urology, Nara Medical
University, 840 Shijo-cho, Nara 634-8522, Japan
E-mail: makitomiyake@yahoo.co.jp
1Funding: JSPS KAKENHI Grant Number 26861290 (M.M.), 15K10605 (K.F.) and
Fiscal Years 2015–2016 Nara Medical University Grant-in-Aid for Collaborative
Research Projects (K.F. and M.M.).
2Conflicts of interest: The authors disclose no potential conflicts of interest.
3 Implications: Tumor-associated macrophages and cancer-associated fibroblasts are
modulated by a CXCL1 signaling that helps cancer progression, with implications for
novel therapeutic opportunities for bladder cancer.
Received 29 April 2016; Revised 5 August 2016; Accepted 11 August 2016
© 2016 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open
access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1476-5586
http://dx.doi.org/10.1016/j.neo.2016.08.002Introduction
Urothelial cancer of the bladder (UCB) is the second most frequent
neoplasm of the urogenital tract, with approximately 74,690 patients
and an estimated mortality of 15,580 in 2014 in the US alone [1].
UCB is a heterogeneous disease. Non-invasive, well-differentiated
tumors (Ta) are relatively indolent, but T1 high-grade (T1HG)-UCB
and muscle invasive bladder cancer (≥T2, MIBC) are known to be
life-threatening [2]. Although a multidisciplinary approach has been
developed, treatment and management of the disease remains
challenging and controversial. To improve the clinical outcome, the
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resistance need to be elucidated.
Tumor tissue is composed of cancer cells and various types of
stromal cells, including endothelial cells, macrophages, and fibro-
blasts. Their interaction and crosstalk might lead to the formation of a
cancer-specific microenvironment for tumor progression.
Tumor-promoting inflammation is known to be one of the hallmarks
of malignancy [3]. Complexity arises from various types of
inflammatory cells, chemokines, and cytokines in solid tumors and
their surrounding areas [4]. The intravesical instillation of Bacillus
Calmette–Guérin (BCG) has been used as an effective immunother-
apy to prevent tumor recurrence and progression in selected patients
with non-muscle invasive bladder cancer (NMIBC) [2], implying that
UCB is a potentially immunogenic disease. Recently, we reported
that the expression of chemokine (C-X-C motif) ligand 1 (CXCL1) is
associated with tumor aggressiveness and angiogenesis in human
UCB and prostate cancer [5–7]. However, only limited data are
available on the biological role and paracrine network of CXCL1 in
the tumor microenvironment of human UCB.
Macrophages are the most abundant stromal cells associated with
the host immune system in the tumoral area, and they have diverse
phenotypes. In the oncology field, macrophages have 2 different
functions, a tumor-suppressive (M1) and a tumor-supportive (M2)
function, which could be a consequence of the different tumor
microenvironments [8,9]. Tumor-associated macrophages (TAMs,
also known as M2 macrophages) are recognized to be oriented
towards promoting tumor growth through enhanced tumorigenesis,
angiogenesis, and suppression of adaptive immunity (M2 function).
TAMs recruited by chemokines such as interleukin (IL)-4 and IL-13 are
a major component of the leukocyte infiltrate in tumors [9,10]. A high
density of tumor-infiltrating TAMs has been shown to be associated with
poor outcomes in various types of cancer, including UCB [11–14].
Fibroblasts are among the most active cell types of the stroma and
perform tissue repair functions under certain physiological conditions
[15]. Cancer-associated fibroblasts (CAFs, also known asmyofibroblasts)
are another major component in the tumor stroma and play a critical role
in tumor growth, angiogenesis, and treatment resistance by secreting
cytokines such as CXCL12, favoring a variety of tumor-specific
mechanisms like epithelial–mesenchymal transition (EMT) [16,17].
Their roles consist of creating a structural matrix around cancer cells,
recruiting new blood vessels, and stimulating the production of proteases
that can degrade adjacent tissues, thereby increasing the likelihood of
tumor development, invasion, and metastasis [18]. A number of studies
addressing the prognostic impact of CAFs in human malignancies,
including UBC, have shown an association between a high density of
CAFs and poor prognosis [19–21]
A complete understanding of the molecular mechanism driving the
interaction and crosstalk between tumor cells and TAMs/CAFs is
essential for overcoming treatment resistance and improving patient
outcome. To date, no study has focused on how TAMs and CAFs
modulate the aggressiveness ofUCB in themediation of CXCL1. In the
present study, we investigated the role of the paracrine effect induced by
TAMs and CAFs in the tumor microenvironment of human UCB.
Materials and Methods
Patient Selection and Data Collection
The Ethics Committee of the Nara Medical University approved
this study, and all participants provided informed consent. The studywas conducted on 155 patients with pathologically diagnosed primary
NMIBC who underwent transurethral resection of bladder tumor
(TURBT) between January 2004 and April 2013. The clinical
information and follow-up data were collected by retrospective chart
review. All hematoxylin and eosin (H&E)-stained specimens
obtained by initial TURBT were reassessed independently by 2
experienced uropathologists (K.S. and N.K.) with regard to T
category (2010 American Joint Committee on Cancer TNM Staging
system), tumor grade (2004 WHO classification), and lymphovas-
cular invasion. Follow-up was performed according to our institu-
tional protocol [2]. Progression was defined as recurrent disease when
there was invasion into the muscularis propria (≥T2), positive lymph
nodes, and/or the occurrence of distant metastases.
Immunohistochemical Staining and Quantification
Immunohistochemical (IHC) staining using paraffin-embedded,
formalin-fixed tissue blocks was performed as previously described
[5]. Antibodies and treatment details are available in the Supple-
mentary Table S1. CXCL1 expression in cancer cells was
semi-quantified as previously described [5]. The proportion and
intensity scores were added to obtain a combined score as follows:
low, intermediate, and high. CD204-positive round cells in the
cancerous area were counted in at least 3 independent high-power
microscopic fields (HPF; 400×, 0.0625 μm2) [14]. The mean
number of macrophages was calculated as tumor-infiltrating TAMs.
The immunoreactivity of αSMA at the tumor border was scored
according to the number of αSMA-positive spindle cells (CAFs) as
follows: 0, almost no CAFs or a small number of CAFs surrounding
less than half of the border; 1, a moderate number of CAFs
surrounding less than half of the border; or 2, a large number of CAFs
surrounding more than half of the border [22]. To quantify the
expression level of MMP2, E-cadherin, and IL-6 in UBC cells,
immunoreactive tumor cells were counted in at least 3 independent
fields, and the percentage of positive cells was calculated by dividing
that number by the total counted cancer cells (1–100%). Evaluation
was carried out by 2 investigators (M.M. and Y.T.) blindly, without
knowledge of the patients’ outcome or other clinicopathological
characteristics.
Cell Lines and Reagents
Four bladder cancer cell lines, J82, UMUC3, T24 (ATCC,
Manassas, VA, USA), MGH-U3 (a generous gift from Dr H. LaRue
at Laval University Cancer Research Centre, Quebec, Canada),
benign bladder cell line UROtsa (a generous gift from Dr Donald
Sens at the University of North Dakota School of Medicine, Grand
Forks, ND, USA), acute monocytic leukemia cell line THP-1
(ATCC), mouse dermal fibroblast cell line NIH3T3 (ATCC), and
HEK293FT (Invitrogen, Carlsbad, CA, USA) were used in the
present study. Cell lines were authenticated by analysis of their
genetic alterations. Cell lines were maintained in DMEM or
RPMI-1640 media supplemented with 10% fetal bovine serum
(FBS), 100 units/mL penicillin, and 100 μg/mL streptomycin in a
standard humidified incubator at 37°C in 5% CO2.
Phorbol-12-myristate-13-acetate (PMA) was purchased from
Cell Signaling Technology (Beverly, MA, USA). Recombinant
proteins, CXCL1 (R&D Biosystems, Minneapolis, MN, USA),
TGF-β (Wako Pure Chemical, Osaka, Japan), IL-4, and IL-6
(Prospec, East Brunswick, NJ, USA) were used in the described
experiments.
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Western blotting was performed as previously described [23]. The
primary antibodies used in this study were anti-CXCL1 (dilution,
1:500), anti-CD204 (dilution, 1:2,000), anti-αSMA (dilution,
1:10,000), and anti-actin antibody (dilution, 1:20,000; clone AC-15,
Sigma-Aldrich, St Louis, MO, USA) as an internal loading control.
Generation of TAMs from THP-1 and CAFs from NIH3T3
To generate TAMs from monocytic THP-1, cells were seeded at 2 ×
105 cells/cm2 and treated with PMA (200 nM) for 24 h for
differentiation into resting macrophages (M0 cells). For M2 polariza-
tion, cells were treated with IL-4 (20 ng/mL) for an additional 48 h. To
generate CAFs from NIH3T3, 70% confluent cells grown on dishes or
flasks were activated with TGF-β (20 ng/mL) for 48 h. To confirm the
generation of TAMs and CAFs, western blot analysis for CD204 and
αSMA, respectively, was performed.
Dual Immunofluorescence Staining of Human Bladder
Cancer Tissue
Dual immunofluorescence staining was performed with antibodies
specific to CXCL1/CD204 or CXCL1/αSMA (goat polyclonal/
mouse monoclonal). Briefly, paraffin sections were placed on glass
slides and subjected to deparaffinization and antigen retrieval with
citric acid, followed by blocking in 1% BSA for 1 h. The sections were
incubated in anti-CXCL1 (dilution, 1:100) and CD204 (dilution,
1:200) or αSMA (dilution, 1:1,000) for 1 h at room temperature and
rinsed thrice in PBS. The sections were incubated in Alexa Fluor 594
anti-goat IgG and Alexa Fluor 488 anti-mouse IgG secondary antibody
(dilution, 1:500; Life Technologies) for 30 min and mounted with
mounting medium with DAPI (Vector Laboratories, Burlingame, CA,
USA). The sections were immediately examined under a fluorescence
microscope (Leica DMI 4000B, Wetzlar, Germany).
Real-Time Reverse Transcription PCR
RNA extraction and real-time RT-PCR were performed as
previously described [23].
The gene-specific TaqMan primer and probe sets used in this study
were Hs00236937_m1 for human CXCL1, Hs01891184_s1 for
human CXCR2, Hs01060665_g1 for human β-actin,
Mm04207460_m1 for mouse CXCL1, Mm99999117_s1 for
mouse CXCR2, and Mm01324804_m1 for mouse β-actin. Relative
fold changes in mRNA levels were calculated after normalization to
β-actin using the comparative Ct method.
Lentivirus Production and Infection for CXCL1 Overexpression
For lentivirus production, CXCL1 expression vector
(EX-G0095-Lv105) or its empty control (Lv105CT; GeneCopoeia,
Rockville, MD, USA) and Virapower packaging mix plasmids (pLP1,
pLP2, and pLP/VSVG; Life Technologies) were mixed and
transfected into 293FT cells using Calphos Mammalian Transfection
Kit (Clontech, Palo Alto, CA, USA) according to the manufacturer’s
instructions. Forty-eight hours after transfection, the supernatant
containing the lentivirus was produced in HEK-293FT, collected,
and filtered. The culture medium of THP-1 and NIH3T3 cells
seeded on 35-mm dishes was half-replaced with virus-containing
supernatant supplemented with 4 μg/mL polybrene and incubated
overnight. Then, medium was replaced, and stable transfectants were
selected with 2 μg/mL of puromycin (Sigma-Aldrich) for 14 days and
subcloned by limiting dilution in 96-well plates. Integration of thetransfected gene was confirmed by western blotting. Stable cell lines
were maintained in media containing 2 μg/mL of puromycin for
THP-1 and NIH3T3 clones.
Cell Invasion Assay Using Conditioned Media Obtained from
TAMs and CAFs
THP-1-derived TAMs or NIH3T3-derived CAFs were seeded
onto 6-well plates at a density of 200,000 cells/well in
serum-containing media. Twenty-four hours later, the medium was
replaced with serum-free RPMI1640 medium, and cells were
incubated for additional 48 h. The conditioned medium was
collected from manipulated TAMs and CAFs, followed by
centrifugation to remove cells or cell debris. The invasion assay was
performed with the BD Falcon FluoroBlok Insert System according
to the manufacturer’s directions. Briefly, 24-well plates with 8-μm
pore membranes were coated with 200 ng/mL growth factor reduced
Matrigel (BD Biosciences, San Jose, CA). MGH-U3 or T24 cells
were added to each insert at a density of 25,000 cells/well in the
conditioned media described above. The lower chamber contained
RPMI1640 media with 10% FBS as a chemoattractant. The cells
were maintained in a humidified incubator with 5% CO2 at 37°C for
48 h. The cells attached to the bottom of the membrane were stained
for 30 min with the cell viability indicator Calcein AM Fluorscent
Dye (PromoKine, Heidelberg, Germany) and quantified using a
microplate spectrophotometer (Infinite 200M PRO; Tecan, Männedorf,
Switzerland) at 495 mm excitation and 515 nm emission. Cells were
examined by fluorescent microscopy.
Three-Dimensional Co-Culture of Urothelial Cancer Cells and
TAMs/CAFs
UCB cells (MGH-U3 and T24) and THP-1-derived TAMs or
NIH3T3-drived CAFs were co-cultured on 96-well NanoCulture plate
with amicro-square pattern (SCIVAX,Kanagawa, Japan). Before seeding,
UCB cells were labeled with the green-fluorescent dye PKH-67
(Sigma-Aldrich), and TAMs/CAFs were labeled with the
red-fluorescent dye PKH-26 (Sigma-Aldrich). UCB cells and TAMs or
CAFs (CXCL1 expression or empty control) seeded at the same cell
number (5×103 cells/well) were plated and incubated for 3 days.
Anti-CXCL1-neutralizing antibody (ab89318; Abcam, Cambridge, MA,
USA) was used to inhibit CXCL1 function in the co-culture experiments.
Spheroid formation was examined by fluorescent microscopy.
Animal Experiments and Monitoring
Approval for the animal studies was obtained from the Committee
on Animal Research of the Nara Medical University. Specific
pathogen–free 6-week-old athymic BALB/c nu/nu mice and
C.B-17/severe combined immunodeficiency (SCID) mice were
used (Oriental Bio Service, Kyoto, Japan). At least 8 animals were
included in each group.
The subcutaneous tumorigenicity assay was performed in nude
mice by injecting bladder cancer cells (1×106) and TAMs or CAFs
(0.5×106) in a 1:1 mixture of Matrigel. Tumor diameters were
measured twice a week with electronic calipers, and tumor volumes
were calculated using the following formula: {(width)2×length}/2 (mm3).
The mice were killed on day 21, and the tumors were resected for IHC
staining analysis. To generate the orthotopic bladder tumor models,
UMUC3 (2×106) and TAMs or CAFs (1×106) were injected into the
bladder cavity of SCID mice by 24-gauge angiocatheters (Surflo;
Terumo Corp, Tokyo, Japan) as described previously [24]. Two weeks
Figure 1. CXCL1 expression and recruitment of stromal cells in human non-muscle invasive bladder cancer. (A) Representative expression
statusofCXCL1,CD204,αSMA,MMP2, andE-cadherin in humanbladder cancer tissues.All imageswere captured at 200×magnification except for
αSMA, forwhich the imageswerecapturedat100×and400×magnification. (B)Progression-freesurvival curvesofpatientswithNMIBCafterTURBT
according to theexpression level ofCXCL1. (C–F) comparisonofCXCL1expression levelswith (C) thenumberof tumor-infiltratingTAMs, (D) induction
level ofCAFs (CAF score), (E) percentageofMMP2-positive cells, and (F) percentageofmembranousE-cadherin-positive cells. In thebox-and-whisker
plot or bar charts, significance (* P b 0.05, ** P b 0.05) was assessed by the Mann–Whitney U test.
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intravesical tumor implantation rate by H&E staining and assessed by
IHC for CD204, αSMA and E-cadherin.
Statistical Analysis
Progression-free survival (PFS) and intravesical recurrence-free
survival from the day of initial TURBT were obtained using the
Kaplan–Meier method and compared by the log-rank test or log-rank
test for trend. Data are expressed by bar charts or box plots, and
Student’s t-test or the Mann–Whitney U-test was applied for
statistical analysis as appropriate. The interrelationship between IL-6
expression and tumor-infiltrating TAM was examined using Spear-
man’s correlation. IBM SPSS Version 21 (SPSS Inc., Chicago, IL,
USA) and PRISM software version 5.00 (San Diego, CA, USA) were
used for statistical analyses and plotting the data, respectively. P b
0.05 was considered statistically significant.
Results
Correlation of CXCL1 Expression with Clinicopathological
Features and Treatment Outcome in NMIBC
The clinicopathological characteristics of 155 NMIBC cases are
outlined in Supplementary Table S2. Representative images of IHC
staining of CXCL1, CD204, αSMA, MMP2, and E-cadherin areshown in Figure 1A. CXCL1 was expressed predominantly in the
cytoplasm of tumor cells. Strong CXCL1 expression was observed in
the tumor tissue of the T1 high-grade tumors, whereas the expression
level of CXCL1 was relatively lower in the Ta low-grade tumors
(Figure 1A, first panel). When compared with clinicopathological
variables, a higher CXCL1 expression score was associated with higher
T category and tumor grade (Supplementary Table S2. In addition,
Kaplan–Meier analysis showed that a high CXCL1 expression score was
associated with a high risk of disease progression (Figure 1B).
Next, quantitative assessment of TAM, CAF, MMP2, and
E-cadherin expression was performed and compared with the
CXCL1 expression score. Higher levels of CXCL1 expression in the
tumors were associated with a higher number of tumor-infiltrating
TAMs (Figure 1C), enhanced recruitment of CAFs to the tumoral
area (Figure 1D), higher expression of MMP2 (Figure 1E), and lower
expression of E-cadherin (Figure 1F). These findings suggest that
CXCL1 expression in cancer cells exhibits aggressiveness and poor
clinical outcome by modifying the tumor microenvironment.
Induction of TAMs and CAFs by IL-6 Overexpression
Conversion into TAMs and CAFs has been found to be involved in
IL-6 expression in some types of malignancy [9,25]. To investigate
whether IL-6 expression in human UCB was associated with the
conversion, additional IHC analysis was performed. Figure 2A shows
Figure 2. Induction of TAMs and CAFs by IL-6 in human bladder cancer tissues and confirmation by in vitro experiments.
(A) Representative expression status for IL-6 in human bladder cancer tissues. Images were captured at 200× magnification. (B) The
interrelationship between the percentage of IL-6-positive cancer cells and the number of tumor-infiltrating TAMs was examined using
Spearman’s correlation. Spearman r was found to be 0.68 (95% confidence interval, 058–0.76). (C) Comparison of the percentage of
IL-6-positive cancer with the induction level of CAFs (CAF score). (D) Morphological changes of THP-1 cells by PMA and IL-4 treatment.
THP-1 cells were treated with 200 nM PMA for 24 h to differentiate them into resting macrophages (middle), followed by treatment with
IL-4 (20 ng/mL) for 48 h (right). (E) Western blot analysis for confirming the generation of TAMs and CAFs. THP-1 cells were treated with a
combination of PMA and 20 ng/mL of CXCL1, IL-6, or TGF-β, separately. Upregulation of CD204 indicates differentiation into TAMs.
NIH3T3 cells were treated with 20 ng/mL of CXCL1, IL-6, or TGF-β, separately. Upregulation of αSMA indicates the activation of
fibroblasts, which are known to be CAFs.
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rate of IL-6-positive cells was correlated with higher
tumor-infiltrating TAM or higher CAF score (Figure 2B and C).
To confirm the generation of TAMs from THP-1, THP-1 cells were
treated with PMA alone or PMA+IL-4. PMA treatment induced
resting macrophages (M0 cells), and PMA treatment followed by IL-4
stimulation induced growing M2 macrophages (Figure 2D). Before
treatment, THP-1 cells were round, floating, and did not attach to the
bottom surface of the culture dish. After treatment with TPA and
IL-4, they adhered to the bottom surface with abundant cytoplasmic
projections. Western blot analysis revealed that, like IL-4, CXCL1 or
IL-6 stimulation upregulated the CD204 expression of THP-1,
suggesting that both CXCL1 and IL-6 were potential inducers of
TAM from monocytes (Figure 2E). Morphological changes similar to
those observed with IL-4 treatment were found with CXCL1 and
IL-6 treatment as well. In addition, like IL-4, CXCL1 or IL-6
stimulation upregulated αSMA expression in NIH3T3 cells,
suggesting that both CXCL1 and IL-6 were potential inducers of
CAFs from normal fibroblasts (Fig. E). These results implied that
both CXCL1 and IL-6 from cancer cells were associated with
recruitment and induction of TAMs and CAFs in human UCB.
CXCL1 Produced by TAMs and CAFs Around the Tumoral
Area Promotes the Invasion Capability of UCB
To investigate whether TAMs and CAFs around the tumoral area
produce CXCL1, dual immunofluorescence staining was performed
with antibodies specific to CXCL1/CD204 or CXCL1/αSMA. The
representative images from fluorescent microscopy showed that some
TAMs and CAFs around the tumoral area produced CXCL1.To explore the role of CXCL1-expressing TAMs and CAFs in
the tumor microenvironment of UBC, cell line-based experiments
were performed. The endogenous expression levels of CXCL1 and
CXCR2 in 5 epithelial cell lines, as well as the THP-1 and NIH3T3
cell lines, were evaluated by real-time RT-PCR. J82, UMUC3, and
T24 (known as poorly differentiated high-grade UCs) expressed
higher levels of CXCL1 compared to UROtsa (derived from normal
urothelia) and MGH-U3 (derived from low-grade/low-stage UC).
There was no endogenous expression of CXCL1 in THP-1 or
NIH3T3 cells (Figure 3B). CXCR2 was expressed in all the cell
lines, whereas a slightly higher expression level of CXCR2 was
observed in MGHU3, THP-1, and NIH3T3 cells compared to
that in UROtsa, J82, UMUC3, and T24 cells (Supplementary
Figure S1).
After lentiviral infection and puromycin selection, CXCL1
expression and CD204/αSMA markers were confirmed by western
blotting analysis. CXCL1 expression occurred in LvCXCL1-THP-1
and LvCXCL1-NIH3T3 as opposed to no expression in the
corresponding controls (LvNega). The induction of CXCL1 in
NIH3T3 cells resulted in slightly elevated αSMA (Figure 3C).
Following our hypothesis that high CXCL1 production in the TAMs
and CAFs around the tumoral area would enhance tumor
invasiveness, an in vitro invasion assay was carried out. In the
invasion assay, we treated MGH-U3 and T24 bladder cancer cells
with conditioned media obtained from manipulated THP-1-derived
TAMs and NIH3T3-derived CAFs infected with the lentiviral vector.
The invasion capability of both UCB cells was significantly
enhanced when treated with media from LvCXCL1-TAMs and
LvCXCL1-CAFs (Figure 3D).
Figure 3. Association of CXCL1 production in TAMs/CAFs with invasion potential of human bladder cancer. (A) Dual immunofluorescence
staining analysis for CD204 or αSMA (green) and CXCL1 (red) shows the expression of CXCL1 in TAMs and CAFs in the tumoral area.
Overlay images and their magnified images are shown (2 panels on the right). Original magnification, 200×. (B) CXCL1 mRNA expression
level was determined by real-time RT-PCR. Expression levels are the result of 3 experiments and are expressed as the mean ± SD relative
to that of UROtsa, which is defined as 1. (C) THP-1 and NIH3T3 cells were infected with lentiviral constructs harboring empty vectors
(LvNega) or CXCL1 expression vectors (LvCXCL1). Western blot analysis demonstrated altered CXCL1 expression in both cell lines. The
changes in the expression levels of CD204 and αSMA were evaluated in infected THP-1 and NIH3T3 cells, respectively. Actin served as
the loading control. (D) MGH-U3 and T24 cells were suspended in the conditionedmedia collected frommanipulated TAMs and CAFs and
subjected to in vitro invasion assays. Data are expressed as the mean ± SD of 3 independent experiments conducted in triplicate; *, P b
0.05, **, and P b 0.01.
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Adhesion of Bladder Cancer Cells with TAMs and CAFs
To recognize the cell-to-cell adhesion between UCB cells and TAMs
or CAFs in 3D co-culture, CXCL1-expressing TAMs and CAFs were
mixed with UCB cells and seeded. These cells were identified by a dual
fluorescence detectionmethod. Representative pictures of co-localization
and adhesion of UCB cells/TAMs and UCB cells/CAFs are shown
in Figure 4. As compared with empty vector-transfected TAM
(LvNega-TAM), the cell-to-cell adhesion rate of UCB cells/TAMs was
significantly greater and formed more homogenous and larger spheroids
in LvCXCL1-TAM (Figure 4A). Despite the endogenous expression ofCXCL1 in T24 cells (Figure 3B), CXCL1 produced by TAMs has a
significant role in the adhesion between UCB cells and TAMs. Notably,
adhesion between UCB cells and TAMs and the growth of spheroids
were significantly inhibited by treatment with anti-CXCL1-neutralizing
antibody (Figure 4B). UCB cells and TAMs did not merge but, instead,
separately formed spheroids of each cell type. Similar results were
obtained in the experiments for adhesion and interaction between UCB
cells and CAFs (Figure 4C andD). These findings suggested that both of
CXCL1 produced by UCB cells and CXCL1 produced by TAMs or
CAFs play an important role in the adhesion and interaction between
these cells.
Figure 4. Association of CXCL1 production in TAMs/CAFs with strong adhesion to bladder cancer cells and formation of homogenous
multicellular spheroids. Bladder cancer cells T24 and MGH-U3 were labeled with PKH67 (green dye). THP-1-derived TAMs and
NIH3T3-drived CAFs were labeled with PKH26 (red dye). After labeling, cancer cells and stromal cells were mixed at the same number
(5×103 cells/well) and plated into a 3D culture plate. Photographs of randomly selected spheroids were captured 3 days after plating.
Representative spheroids are shown as follows: (A) spheroids of the co-culture of T24 cells and TAMs; (B), spheroids of T24 cells and
TAMs treated with anti-CXCL1-neutralizing antibody; C, spheroids of the co-culture of MGH-U3 cells and CAFs; (D) spheroids of MGH-U3
cells and CAFs treated with anti-CXCL1-neutralizing antibody. Original magnification, 400×.
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and Intravesical Implantation in in Vivo Bladder Cancer Models
To investigate the in vivo influence of CXCL1 production in
TAMs and CAFs, we used 2 different types of in vivo experimental
models of bladder cancer. In the subcutaneous xenograft model, we
inoculated bladder cancer cells together with the manipulated TAMs
or CAFs. The proliferation ability of the mixture of
LvCXCL1-TAMs/LvCXCL1-CAFs and cancer cells was significantly
higher than that of the mixture of LvNega-TAMs/LvNega-CAFs and
cancer cells or cancer cells only (Figure 5A-D). The difference in
21-day tumor size between LvCXCL1-TAMs and LvNega-TAMs, as
well between LvCXCL1-CAFs and LvNega-CAFs, was more pro-
nounced in MGH-U3 than in UMUC3. IHC staining for CD204,
αSMA, and E-cadherin demonstrated that CXCL1 overexpression in
TAMs and CAFs enhanced subcutaneous tumor growth of bladder
cancer cell lines by increased recruitment of stromal cells, EMT
promotion by decreased membranous expression of E-cadherin, and
increased invasion phenotype byMMP2 expression. There were higher
numbers of tumor-associated stromal cells in the tumors inoculated
with CXCL1-overexpressing TAMs and CAFs (Figure 5E).
Next, we used the orthotopic bladder cancer model with SCIDmice
to evaluate the potential of implantation in the bladder. We inoculated
UMUC3 bladder cancer cells into the murine bladder together with the
manipulated TAMs or CAFs. Twoweeks after inoculation, the bladders
were resected, and tumor implantation was identified byH&E staining.
We pathologically confirmed the successful implantation of UMUC3
cells in murine bladders (Figure 5F). Bladder tumors inoculated with
LvCXCL1-TAMs and LvCXCL1-CAFs were apparently larger than
those inoculated with control cells (LvNega). The implantation rate was
significantly higher in the murine bladders inoculated with TAM- andCAF-LvCXCL1 as compared to those inoculated with control cells
(Figure 5G). In the intravesical inoculation of themixture of cancer cells
and TAMs, 3 out of 8 murine bladders (37.5%) harbored tumors,
whereas 6 out of 8 (75.0%) did not. Regarding the CAFs, 2 out of 8
murine bladders (25.0%) harbored tumors, whereas 7 out of 8 (87.5%)
did not. Thus, CXCL1 production in the TAMs andCAFs supports the
attachment of bladder cancer cells to the bladder wall and the
consequent tumor growth in the orthotopic bladder condition. To
investigate whether higher levels of tumor-infiltrating TAMs and CAFs
around the tumoral area are associated with a higher risk of bladder
cancer recurrence after TURBT in human NMIBC, recurrence-free
survival curves were generated and compared by the number of TAMs
and the CAF score in the IHC staining (Figure 5H). Higher number of
TAMs (≥25TAMs/HPF) correlated with a higher risk of bladder cancer
recurrence (P = 0.03), while an increased risk of bladder cancer recurrence
in the tumors with high levels of CAF (CAF score = 2) was observed as
compared to those with low levels of CAF (CAF score = 0/1); however,
the difference did not reach statistical significance (P = 0.18).
Discussion
CAFs have been reported to contribute to a tumor-permissive
inflammatory environment, while TAMs display immunosuppressive
and tumor-promoting behaviors, including pro-metastatic function
by the expression of angiogenesis factors and MMPs [20]. Although
many efforts have been made to clarify the crosstalk and interaction
between these stromal cells and cancer cells, the complete picture
remains obscure. Considering that intravesical instillation of BCG is
widely used as an effective immunotherapy, bladder cancer cells have
a strong linkage to inflammatory and immunologic cells. Moreover,
several recent clinical trials for novel immunotherapies targeting
Figure 5. Subcutaneous xenograft models and orthotopic bladder cancer models using human bladder cancer cells, TAMs, and CAFs. (A)
MGH-U3 cells (1×106) mixed with LvCXCL1-TAMs or LvCXCL1-TAMs (0.5×106) and MGH-U3 cells (1×106) not mixed with TAM were
injected subcutaneously into athymic nude mice. Similar experiments were conducted using UMUC3 cells and TAMs (B), MGH-U3 cells
and CAFs (C), and UMUC3 cells and CAFs (D). Tumor size, recorded over 21 days, was plotted as mean ± SD for the 3 groups (n = 8/
group). Tumor sizes on the 21st day were compared by the Mann–Whitney U test (* P b 0.05, ** P b 0.05; ns = no significance). (E) The
resected tumors were analyzed by immunohistochemical staining for CD204, αSMA, E-cadherin, and MMP2. Representative pictures for
tumors of MGH-U3/TAMs and MGHU-3/CAFs are shown. (F and G) The orthotopic models using SCID mice were generated by injecting
the mixture of MGH-U3 cells (2×106) and the manipulated TAMs or CAFs (1×106). Two weeks after injection, the bladders of mice were
resected to evaluate intravesical tumor implantation rate by H&E staining for each group (n = 8/group). (H) Intravesical recurrence-free
survival curves in patients with NMIBC after TURBT according to the number of tumor-infiltrating TAMs (left) and the CAF score (right).
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Figure 6. Schematic diagram of the proposed mechanism for
crucial roles of CXCL1 in human urothelial carcinoma of the
bladder. TAM, tumor-associated macrophage; CAF, cancer-
associated fibroblast; CXCL1, chemokine (C-X-C motif) ligand 1;
MMP, matrix metalloprotease.
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[26–28]. However, some of the treated patients experience disease
relapse or treatment failure. The molecular mechanisms of how
stromal cells like CAFs and TAMs in UCB affect aggressiveness and
resistance to these immunotherapies needed to be unveiled to
improve the clinical outcome.
In an earlier study, we found that the expression of CXCL1 was
associated with tumor aggressiveness and angiogenesis in human UCB
[5,7]. In 2012, Acharyya et al. demonstrated that elevated CXCL1
attracts CD11b+Gr1+ myeloid cells into the tumor, which produce
chemokines, including S100A8/9, resulting in breast cancer cell survival
[29] . The authors conc luded tha t th i s network o f
endothelial-carcinoma-myeloid signaling interactions was associated
with chemoresistance and metastasis through the CXCL1/2-S100A8/9
loop. However, there is only limited information about the role of
CXCL1 on the paracrine network in the tumor microenvironment of
human UCB. Thus, we first investigated whether the CXCL1
expression level in UCB influenced TAM and CAF recruitment and
metastatic potential using E-cadherin and MMP2, which are known as
prognostic markers of UCB. Robust associations of higher CXCL1
expression with enhanced recruitment of both TAMs and CAFs, higher
metastatic potential, and decreased PFS were observed (Figure 1).
MMP2 has been suggested to play essential roles in tumor invasion and
progression. TAMs and CAFs around the tumors produce growth
factors, chemokines, and extracellular matrix components such as
collagen I/IV, fibronectin, and tenascin-C. They also secrete protein
acidic and rich in cysteine (SPARC), which might be facilitating the
angiogenic recruitment of endothelial cells and pericytes [30]. This
dynamic reprogramming is regulated by membrane type 1 matrix
metalloproteinase (MT1-MMP), which triggers tumor invasion
indirectly by activating MMP2 function and directly by degrading
the extracellular matrix [31]. Moreover, pre-metastatic niches formed
by invading bone marrow-derived cells (BMDCs) facilitate tumor cells
to metastasize. Lysyl oxidase plays a critical role for pre-metastatic nicheformation. High levels of MMP2 leads to the cleavage of collagen IV,
thereby enhancing the invasion and recruitment of additional BMDCs
and metastasizing tumor cells [32].
In previous studies, polarization/activation of TAMs and induc-
tion/recruitment of CAFs were found to be regulated by tumor
cell-derived molecules such as IL-6 [11,33]. We hypothesized that
IL-6 signaling from bladder cancer cells mediates the recruitment of
these stromal cells. IHC staining analysis showed a positive
relationship between IL-6 expression levels of cancer cells and
induction levels of TAMs/CAFs (Figure 2A–C). In addition, IL-6
stimulation, as well as CXCL1 stimulation, upregulated CD204 and
αSMA expression levels in THP-1-derived macrophages and
NIH3T3-derived CAFs, respectively. These findings suggest that
besides CXCL1 paracrine signaling, IL-6 signaling between cancer
cells and stromal TAMs/CAFs could represent a key factor for
creating the tumor microenvironment of human UCB. This result is
supported by previous reports of the association of IL-6 and TAM/
CAF induction [34–36].
Two-dimensional (2D) monolayer cell culture is a simple method;
however, it does not reflect physiological conditions. In this study, we
tried the 3D co-culture method of cancer cells and TAMs/CAFs to
recognize the cell-to-cell adhesion between UCB cells and stromal
cells. Cancer cells and TAMs/CAFs form multicellular mixed
spheroids in which cells are exposed to a gradient of hypoxia, thus
reflecting the actual human tumor biology more closely than that by
2D co-culture. UCB is one of the most hypoxic solid tumors, and
HIF-1α levels are higher in cancer tissue than in normal urothelial
tissue [37]. Here, we found that that CXCL1 produced in TAMs and
CAFs acted in a paracrine fashion and exhibited enhanced cell-to-cell
adhesion of TAMs/CAFs with cancer cells.
Desmoplasia comprises a dense stromal fibro-inflammatory
reaction of fibroblasts, inflammatory cells, and tumor vasculature.
Recent studies have suggested that hypoxia and subsequently elevated
HIF-1α increase desmoplasia by upregulating the formation of sonic
hedgehog ligand by pancreatic cancer cells, which activate hedgehog
signaling and stimulate the formation of collagen I and fibronectin by
fibroblast cells [38]. This phenomenon can facilitate close
pro-tumorigenic communication between cancer cells and stromal
cells, resulting in limiting drug delivery and chemoresistance due to
promotion of desmoplasia.
We used 2 different in vivo approaches for confirming the role of
CXCL1 produced in TAMs and CAFs around the cancer cells: the
subcutaneous xenograft model and the orthotopic bladder tumor
model. As we hypothesized, CXCL1 produced in TAMs and CAFs
played critical roles in tumor growth and cell implantation,
respectively (Figure 5A–G). Interestingly, higher numbers of
tumor-infiltrating TAMs and CAFs around the tumors were linked
with a higher risk of intravesical recurrence (Figure 5H). In the
management of NMIBC, appropriate control for intravesical
recurrence after TURBT is as important as control of disease
progression. Multifocality and frequent recurrence are characteristic
features of UCB and UC of the upper urinary tract. Many of the
intravesical recurrences are not life-threatening but can affect the
patient’s quality of life because intravesical recurrence requires
repeated treatments, including TURBT. Previous molecular studies
based on IHC, loss of heterozygosity, and mutation analysis of TP53
demonstrated that intraluminal cell seeding might be an important
mechanism of multifocal occurrence and UCB recurrence [39,40].
Our findings suggested that inhibition of CXCL1 signaling between
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recurrence after TURBT.
On the basis of our results, we propose the mechanism whereby
CXCL1 exerts a crucial influence on human UCB (Figure 6). CXCL1
is expressed in human UCB, especially in high-grade and high-stage
tumors, and is secreted to the stromal area or bloodstream. The
chemotactic roles of CXCL1 and IL-6, as well as hypoxic conditions,
induce and recruit TAMs and CAFs into the tumoral area, leading to
the assemblage of tumor microenvironment-favoring cancer cells
[41,42]. Both TAMs and CAFs supply CXCL1 and other growth
factors to cancer cells in return, which promotes close communication
and interaction between cancer cells and TAMs/CAFs. As a result,
CXCL1 signaling in the tumor microenvironment may be responsible
for repeated intravesical recurrence and disease progression. Disrupt-
ing this signaling pathway provides an alternative approach for the
treatment of the CXCL1-dependent drive in UCB and may also help
to enhance the delivery of chemotherapy.
Conclusion
Knowledge of the actual involvement of these stromal cells in the
development of UCB will facilitate the search for new therapies targeting
the stromal component of bladder cancers. Inhibiting CXCL1 signaling,
which can lead to the aberrant regulation of this chemokine, is a
promising therapeutic approach for human UCB. Currently, there is no
available inhibitor of CXCL1 in the clinical setting.Novel small-molecule
inhibitors, neutralizing antibodies, or anti-sense nucleotides disrupting
CXCL1 signaling need to be developed and tested in patients with
bladder cancer refractive to conventional therapies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.08.002.
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